REG - Immupharma PLC - Launch of Website; Corporate Update

ImmuPharmaAnnouncement

23/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251023:nRSW4760Ea&default-theme=true

RNS Number : 4760E  Immupharma PLC  23 October 2025

 

23 October 2025

ImmuPharma PLC

("ImmuPharma" or the "Company")

Launch of New Website & Corporate Update

www.immupharma.co.uk (http://www.immupharma.co.uk)

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, is delighted to announce the launch of its new corporate website,
marking another step in the Company's scientific and corporate evolution and
placing its proprietary P140 autoimmune platform at the forefront of its
strategy.

Website Showcase | P140 Platform - Scientific Advancement and Mechanism of
Action

P140 is a first-in-class peptide-based therapy designed to address the root
cause of autoimmune and inflammatory diseases.

Unlike current therapies that aim to suppress or modulate immune activity,
P140 selectively restores immune balance without compromising healthy immune
function.

By directly targeting key pathways involved in immune tolerance, P140
represents a new therapeutic category: an immunormalizer.

This targeted mechanism offers the potential for enhanced safety, durability
of response, and applicability across multiple autoimmune conditions.

In conclusion, this unique mechanism aims to rebalance immune homeostasis,
enabling patients to achieve durable remission rather than temporary symptom
control.

Website Showcase | Enabling Precision in Autoimmunity

As also outlined in the new website, ImmuPharma is developing a
next-generation companion diagnostic to P140 designed to identify and monitor
patients with a high level of precision.

Unlike conventional static autoantibody tests, this tool integrates
multi-layered diagnostic logic to guide both patient selection and treatment
adaptation.

This innovative approach enables accurate pre-treatment stratification and
in-treatment monitoring, addressing a critical unmet need in autoimmune
disease (https://sg101101.wpcomstaging.com/science/autoimmunity/)
 management.

Please visit ImmuPharma's website to learn the whole story! Link:
www.immupharma.co.uk (http://www.immupharma.co.uk)

Potential Partnerships and Path Toward Commercialisation

Following the recent key milestone announcement on 1 September 2025,
confirming that a new groundbreaking P140 patent has been filed, providing the
opportunity to extend patent protection for the compound until 2045, the
Company is engaging with a number of potential partners. The Company has a
comprehensive data room which all potential partners, on the signing of a
Confidential Disclosure Agreement, have the opportunity to access the most
recent data and clinical findings, in order to carry out the appropriate due
diligence necessary.

Further updates, as appropriate, will be communicated to the market between
now and our stated objective of completing a deal by the end of 2025.

Financial Update

ImmuPharma's cash runway has recently been extended into H2 2026, by the
exercise of warrants and enhanced monthly cash receipts under the current
Lanstead Capital sharing agreement, the final settlement for which is expected
in November. ImmuPharma has no intention to raise further funds and will look
to further strengthen its cash position as a result of deals with potential
partners.

Tim McCarthy, Chief Executive Officer of ImmuPharma, commented:

"Our new website reflects the exciting transformation taking place at
ImmuPharma, scientifically, corporately, and strategically. The advances
within our P140 autoimmune platform represent a paradigm shift in how
autoimmune therapies will be diagnosed and treated and underlines the strong
scientific foundation and commercial potential of our technology.

A strong statement in our new website but reflective of our focus within the
autoimmune technology space. "Our mission is simple yet bold: to pave the way
to a cure, where most existing approaches focus only on relieving symptoms"."

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550 (about:blank)

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)

 Patrick Claridge, Bob Pountney                                        +44 (0) 20 3650 3650

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives.

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk)

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEAFEAADLSFAA



            Copyright 2019 Regulatory News Service, all rights reserved